EO-1606

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameEO-1606
Drug Alias NameEO-1606
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 mitogen-activated protein kinase inhibitors
TargetsP38 mitogen-activated protein kinase
Therapy Area/IndicationsDermatitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLeo Pharma A/S
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLeo Pharma Inc
Active IndicationsN/A
Inactive IndicationsDermatitis

Other Information

ATC CodeN/A
Related LinksN/A